FDA digital therapeutic Archives

Digital Therapeutics
News

Click Therapeutics Receives FDA Clearance for Motivista for Negative Symptoms of Schizophrenia

Overview The News Click Therapeutics has received FDA 510(k) clearance for Motivista (CT-155), a smartphone-based prescription digital therapeutic indicated for treating negative symptoms of schizophr...

Philip Gates

October 7, 2026

Browsing Tag: FDA digital therapeutic

Click Therapeutics Receives FDA Clearance for Motivista for Negative Symptoms of Schizophrenia

Featured Posts

Oku Digital Health Launches Platform to Connect Real-World Ocular Data With Drug Development

Cigna Healthcare Introduces Health Sense to Personalize Health and Clinical Support

Click Therapeutics Receives FDA Clearance for Motivista for Negative Symptoms of Schizophrenia

Browsing Tag: FDA digital therapeutic

Click Therapeutics Receives FDA Clearance for Motivista for Negative Symptoms of Schizophrenia

Social Icons

Featured Posts

Oku Digital Health Launches Platform to Connect Real-World Ocular Data With Drug Development

Cigna Healthcare Introduces Health Sense to Personalize Health and Clinical Support

Click Therapeutics Receives FDA Clearance for Motivista for Negative Symptoms of Schizophrenia